ESPEROCT

Novo Nordisk Canada Inc🇨🇦 Health Canada

Approval Id: 1fa4c8a3cc9c44cb
Drug Approval Canada Name: ESPEROCT
Product Name: ESPEROCT
Status: Marketed
Status Date: 2022-09-15
Original Market Date: 2022-09-15
Din: 02490102
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Schedule D
Ahfs: 20:28.16
Atc Original: B02BD02 COAGULATION FACTOR VIII
Atc Name: b 02 bd 02
Aig Number: 0161610005
Company Name: Novo Nordisk Canada Inc
Company Address: 101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1

ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED

3000 UNIT / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

1fa4c8a3cc9c44cb

Type

Standard